LETTER TO EDITOR
Year : 2023 | Volume
: 14 | Issue : 1 | Page : 57-
Breakeven point analysis on rotavirus vaccination in the national immunization program: A summary from an Indochina Country
Rujittika Mungmunpuntipantip1, Viroj Wiwanitkit2,
1 Private Academic Consultant, Bangkok, Thailand
2 Depatment of Community Medicine, Dr DY Patil University, Pune, India
Correspondence Address:
Rujittika Mungmunpuntipantip
Private Academic Consultant, 26 Bangkok 11, Bangkok 103300
Thailand
How to cite this article:
Mungmunpuntipantip R, Wiwanitkit V. Breakeven point analysis on rotavirus vaccination in the national immunization program: A summary from an Indochina Country.Int J Prev Med 2023;14:57-57
|
How to cite this URL:
Mungmunpuntipantip R, Wiwanitkit V. Breakeven point analysis on rotavirus vaccination in the national immunization program: A summary from an Indochina Country. Int J Prev Med [serial online] 2023 [cited 2023 Oct 2 ];14:57-57
Available from: https://www.ijpvmjournal.net/text.asp?2023/14/1/57/377526 |
Full Text
Dear Editor,
Rotavirus infection is an important infection in pediatrics. At present, vaccine is available for prevention of this viral infection. In some countries, due to the high prevalence of rotavirus infection, the rotavirus vaccination is already included into the national immunization program. The good examples of country that the rotavirus vaccination is considered for inclusion into the national immunization program are Bhutan and Thailand.[1],[2] Regarding Thailand, rotavirus vaccination is already included at present. As a new vaccine in this setting, there are some reports on medial economic analysis on rotavirus vaccines.[2],[3] In this setting, it is approved that the vaccine is cost-effective than no vaccination.
Nevertheless, an important consideration in implementation of national policies is on the budgeting. There is a need for additional analysis to determine breakeven point of the investment. In this report, the authors retrospectively analyze on the available data[2],[3] to estimate the breakeven point of the rotavirus vaccination program. Conceptually, breakeven point is the point that the investment is equal to gain. From the analysis, within the 5 years, the net expenditure for investment is equal to 8.50–9.36 million USD or 1.70–1.87 USD per year and the gain per year is equal to 13–33 million USD. Based on this data, it can show that the vaccination can reach breakeven point within its first year of implementation. It can show that rotavirus vaccination is useful and medical economic considerable and appropriate preventive medicine policies.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
Pempa, Luz ACG, Luangasanatip N, Kingkaew P, Adhikari D, Isaranuwatchai W, et al. Economic evaluation of rotavirus vaccination in children of Bhutan. Vaccine 2020;38:5049-59.
Saokaew S, Prasitsuebsai W, Bibera GL, Kengkla K, Zhang XH, Oh KB, et al. Economic evaluation of human rotavirus vaccine in Thailand. Infect Dis Ther 2019;8:397-415.
Luangasanatip N, Mahikul W, Poovorawan K, Cooper BS, Lubell Y, White LJ, et al. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand. Vaccine 2021;39:1402-14.
References
| 1 | Pempa, Luz ACG, Luangasanatip N, Kingkaew P, Adhikari D, Isaranuwatchai W, et al. Economic evaluation of rotavirus vaccination in children of Bhutan. Vaccine 2020;38:5049-59. |
| 2 | Saokaew S, Prasitsuebsai W, Bibera GL, Kengkla K, Zhang XH, Oh KB, et al. Economic evaluation of human rotavirus vaccine in Thailand. Infect Dis Ther 2019;8:397-415. |
| 3 | Luangasanatip N, Mahikul W, Poovorawan K, Cooper BS, Lubell Y, White LJ, et al. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand. Vaccine 2021;39:1402-14. |
|
